Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

T-2585.HCl: a novel, potent and selective PDE4 inhibitor with potential as asthma Rx

April 19, 1999

Ebastine is not approvable, FDA tells RPR

April 15, 1999

Fujirebio presents pyrimidine-based compounds useful for hypoxemia

April 15, 1999

U.S. is country of first launch for single-isomer bronchodilator

April 15, 1999

Results from SAR studies on Ariflo presented by SmithKline Beecham at ACS meeting

April 8, 1999

Dual-action antiasthmatic agents described in patent literature by Kowa

April 8, 1999

Pfizer discloses new series of bradykinin antagonists

April 7, 1999

Targeted Genetics reports findings of gene therapy trial in cystic fibrosis

April 6, 1999

Therapeutically useful PDE4 inhibitors in development at ADIR

April 5, 1999

More from ACS meeting: Pfizer presents potent new leukotriene antagonists with oral activity

April 1, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...